Pardeep Nijhawan - Feb 12, 2025 Form 4 Insider Report for Edesa Biotech, Inc. (EDSA)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Stephen Lemieux, Attorney-in-Fact for Pardeep Nijhawan
Stock symbol
EDSA
Transactions as of
Feb 12, 2025
Transactions value $
$0
Form type
4
Date filed
2/14/2025, 05:01 PM
Previous filing
Feb 4, 2025
Next filing
Mar 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDSA Series B-1 Convertible Preferred Shares Award +100 100 Feb 12, 2025 Common Shares 521K $1.92 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Preferred Shares are perpetual and therefore have no expiration date.
F2 Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus all other amounts due in respect of such Preferred Share (excluding distributions), by the conversion price at the time of conversion.
F3 On February 11, 2025, the Reporting Person purchased in a private placement, 100 shares of the Issuer's newly designated Series B-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share for an aggregate purchase price of $1.0 million. The Preferred Shares are immediately convertible at $1.92 per share, to the extent that after giving effect to such conversion the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer.